Entera Bio Warrants (ENTXW) Exercisable at $5.85/Share

TL;DR

**Entera Bio warrants (ENTXW) convert to shares at $5.85 each, watch for potential dilution.**

AI Summary

On January 3, 2024, Entera Bio Ltd. filed an 8-K to report that its warrants, trading under the symbol ENTXW on NASDAQ, are each exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share. This matters to investors because the exercise price of $5.85 per share provides a benchmark for the value at which warrant holders can convert their warrants into actual shares, potentially impacting the company's outstanding share count and stock price if a significant number of warrants are exercised.

Why It Matters

This filing clarifies the terms for warrant holders, which could lead to dilution if many warrants are exercised, increasing the number of outstanding shares.

Risk Assessment

Risk Level: medium — The exercise of warrants at $5.85 per share could dilute existing shareholders if a large number are converted, potentially impacting the stock price.

Analyst Insight

Investors should monitor Entera Bio's stock price relative to the $5.85 warrant exercise price. If the stock trades significantly above this, anticipate potential warrant exercises and subsequent share dilution, which could put downward pressure on the stock price. Consider the impact on per-share metrics.

Key Numbers

• $5.85 — Exercise Price per Ordinary Share (This is the price warrant holders pay to convert their warrants into shares.)

Key Players & Entities

• Entera Bio Ltd. (company) — the registrant filing the 8-K
• $5.85 (dollar_amount) — the exercise price per Ordinary Share for warrants
• January 3, 2024 (date) — date of earliest event reported and filing date
• ENTXW (company) — trading symbol for Entera Bio's warrants on NASDAQ
• NASDAQ (company) — stock exchange where ENTXW warrants trade

Forward-Looking Statements

• If Entera Bio's stock price significantly exceeds $5.85, there will be an increased likelihood of warrant exercises. (Entera Bio Ltd.) — high confidence, target: N/A
• A large-scale exercise of warrants could lead to an increase in Entera Bio's outstanding share count. (Entera Bio Ltd.) — medium confidence, target: N/A

FAQ

Key Financial Figures

• $1.00 b — in compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq
• $1.00 — pany's ordinary shares must be at least $1.00 for at least 10 consecutive business da

Filing Documents

• zk2430720.htm (8-K) — 32KB
• 0001178913-24-000035.txt ( ) — 213KB
• entx-20240103.xsd (EX-101.SCH) — 5KB
• entx-20240103_def.xml (EX-101.DEF) — 18KB
• entx-20240103_lab.xml (EX-101.LAB) — 28KB
• entx-20240103_pre.xml (EX-101.PRE) — 20KB
• zk2430720_htm.xml (XML) — 7KB

01 Other Events

Item 8.01 Other Events. On January 3, 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel (the " Company "), announced that, on December 27, 2023, the Company received an extension of 180 calendar days from the Nasdaq Stock Market LLC (" Nasdaq ") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the " Bid Price Requirement "), following the expiration on December 26, 2023 of the initial 180 calendar-day period to regain compliance . The Nasdaq determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol ENTX. As a result of the extension, the Company has until June 24, 2024 to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 for at least 10 consecutive business days (with such compliance period extendable at the discretion of Nasdaq) prior to June 24, 2024. Nasdaq would then provide a written confirmation of compliance and the matter will be closed. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by June 24, 2024, Nasdaq will provide written notification to the Company that its shares will be subject to delisting. A

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENTERA BIO LTD. Date: January 3, 2024 By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR